OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial

por Salmon-Céron, D, Durier, C, Desaint, C, Cuzin, Surenaud, M, Hénin, Y, Lelièvre, J, Bonnet, B, Pialoux, G, Poizot-Martin, I, Ben Hamouda, N, Jackson, A, Flys, C, Guérin, C, Aboulker, J, Choppin, J, Launay, O
Publicado 2009